Clinical activity of sequential flavopiridol, cytosine arabinoside, and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
Judith E. KarpAmanda L. BlackfordB. Douglas SmithKatrina AlinoAmy Hatfield SeungJavier Bolaños‐MeadeJacqueline M. GreerHetty E. CarrawaySteven D. GoreRichard J. JonesMark J. LevisMichael A. McDevittL. Austin DoyleJames R. Wright
Metrics
Citation History
Topics
Related Documents
Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia
Judith E. KarpB. Douglas SmithMark J. LevisSteven D. GoreJacqueline M. GreerCatherine HattenburgJanet BrielRichard J. JonesJames R. WrightA.D. Colevas
Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia
J. E. KarpElizabeth Garrett‐MayerElihu H. EsteyMichelle A. RudekBenjamin D. SmithJudith M. GreerD. Michelle DryeKatherine MackeyKathleen Shannon DorcySteven D. GoreMark J. LevisMichael A. McDevittHetty E. CarrawayKeith W. PratzDouglas E. GladstoneMargaret M. ShowelMegan OthusL. Austin DoyleJames R. WrightJohn M. Pagel
Sequential mitoxantrone, daunorubicin, and cytosine arabinoside for patients with newly diagnosed acute myelocytic leukemia
Paolo Alberto PaciucciJanet CuttnerArlan J. GottliebRoger B. DavisOrlando J. MarteloJames F. Holland
Mitoxantrone and high-dose cytosine arabinoside in refractory acute myelogenous leukemia
Ronald S. WaltersHagop M. KantarjianMichael J. KeatingWilliam PlunkettElihu H. EsteyB AnderssonM BeranKenneth B. McCredieEmil J. Freireich
Sequential Standard-Dose Cytosine Arabinoside/Mitoxantrone Therapy (SAM) in Adults with Acute Myeloid Leukemia
H. RadtkeJ. SchwambornH. DausD HufnaglR. HerbothJ. PreißH.W. Pees